The world tried to kill Andy off but he had to stay alive to to talk about what happened with databases in 2025.

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...